Revelation Biosciences Financials
This page shows Revelation Biosciences (REVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Repeated equity funding is sustaining a research-driven cash burn while the company keeps a liquid, lightly encumbered balance sheet.
FY2023’s near-breakeven net loss of-$120K did not mark an operating turnaround, because operating loss was still-$8.7M . By FY2025, net loss of-$8.9M sat much closer to operating cash outflow of-$8.3M , meaning reported earnings again resembled the business’s real cash use.
A cash increase in FY2025 was funded externally, not earned internally: financing inflow of
The expense base is still research-heavy: R&D at
Financial Health Signals
Revelation Biosciences does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Revelation Biosciences passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Revelation Biosciences reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Revelation Biosciences's EBITDA was -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.8% from the prior year.
Revelation Biosciences reported -$8.9M in net income in fiscal year 2025. This represents an increase of 40.7% from the prior year.
Revelation Biosciences earned -$23.95 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Revelation Biosciences held $10.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Revelation Biosciences's ROE was -100.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 218.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Revelation Biosciences invested $4.1M in research and development in fiscal year 2025. This represents an increase of 14.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
REVB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $4.1M+14.5% | $3.5M-14.4% | $4.1M-22.9% | $5.4M-22.2% | $6.9M | N/A | N/A |
| SG&A Expenses | N/A | $5.0M+13.1% | $4.4M-1.9% | $4.5M-17.8% | $5.5M+9.0% | $5.0M+3361.2% | $145K | N/A |
| Operating Income | N/A | -$9.1M-13.7% | -$8.0M+7.9% | -$8.7M+20.3% | -$10.9M | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $42K | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Net Income | N/A | -$8.9M+40.7% | -$15.0M-12405.6% | -$120K+98.9% | -$10.8M | N/A | -$1.6M-44718.6% | -$4K |
| EPS (Diluted) | — | -$23.95 | -$1052.16 | -$8.44 | -$149.20 | -$42.50 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
REVB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $11.6M+74.9% | $6.6M-45.8% | $12.2M+121.9% | $5.5M+169.5% | $2.0M-97.2% | $74.2M+327023.7% | $23K |
| Current Assets | $10.8M+64.7% | $6.6M-46.0% | $12.1M+124.4% | $5.4M+183.1% | $1.9M+193.6% | $651K+2772.8% | $23K |
| Cash & Equivalents | $10.7M+64.6% | $6.5M-45.8% | $12.0M+128.3% | $5.3M+312.1% | $1.3M+10763.6% | $12K | N/A |
| Total Liabilities | $2.7M+42.2% | $1.9M-65.6% | $5.6M+25.0% | $4.5M+107.8% | $2.1M-97.0% | $70.8M+268821.6% | $26K |
| Current Liabilities | $2.0M+4.4% | $1.9M-65.6% | $5.6M+25.0% | $4.5M+107.8% | $2.1M-37.6% | $3.4M+12951.2% | $26K |
| Total Equity | $8.9M+88.2% | $4.7M-29.2% | $6.6M+531.6% | $1.1M+1158.1% | -$99K-102.9% | $3.4M+93877.5% | -$4K |
| Retained Earnings | -$49.4M-22.0% | -$40.5M-59.1% | -$25.5M-0.5% | -$25.3M-74.6% | -$14.5M-155.0% | -$5.7M-156410.4% | -$4K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
REVB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.3M | -$8.3M+54.9% | -$18.3M-151.4% | -$7.3M+35.1% | -$11.2M | N/A | -$217K | N/A |
| Capital Expenditures | N/A | N/A | $19K | N/A | N/A | $132K | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$18.3M | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | -$19K | N/A | N/A | -$132K+99.8% | -$74.0M | N/A |
| Financing Cash Flow | $15.7M | $12.5M-2.9% | $12.8M-8.4% | $14.0M-7.7% | $15.2M+89.9% | $8.0M-89.2% | $74.3M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
REVB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Return on Equity | -100.6%+218.8pp | -319.4%-317.6pp | -1.8%+1027.2pp | -1029.0% | N/A | -47.8% | N/A |
| Return on Assets | -77.0%+150.1pp | -227.1%-226.1pp | -1.0%+195.8pp | -196.8% | N/A | -2.2%+13.9pp | -16.1% |
| Current Ratio | 5.41+2.0x | 3.43+1.2x | 2.18+1.0x | 1.22+0.3x | 0.89+0.7x | 0.19-0.7x | 0.86 |
| Debt-to-Equity | 0.31-0.1x | 0.41-0.4x | 0.84-3.4x | 4.23 | N/A | 20.74 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Revelation Biosciences Ranks
Frequently Asked Questions
Is Revelation Biosciences profitable?
No, Revelation Biosciences (REVB) reported a net income of -$8.9M in fiscal year 2025.
What is Revelation Biosciences's EBITDA?
Revelation Biosciences (REVB) had EBITDA of -$9.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Revelation Biosciences's return on equity (ROE)?
Revelation Biosciences (REVB) has a return on equity of -100.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Revelation Biosciences's operating cash flow?
Revelation Biosciences (REVB) recorded an outflow of $8.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Revelation Biosciences's total assets?
Revelation Biosciences (REVB) had $11.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Revelation Biosciences spend on research and development?
Revelation Biosciences (REVB) invested $4.1M in research and development during fiscal year 2025.
What is Revelation Biosciences's current ratio?
Revelation Biosciences (REVB) had a current ratio of 5.41 as of fiscal year 2025, which is generally considered healthy.
What is Revelation Biosciences's debt-to-equity ratio?
Revelation Biosciences (REVB) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Revelation Biosciences's return on assets (ROA)?
Revelation Biosciences (REVB) had a return on assets of -77.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Revelation Biosciences's cash runway?
Based on fiscal year 2025 data, Revelation Biosciences (REVB) had $10.7M in cash against an annual operating cash burn of $8.3M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Revelation Biosciences's Piotroski F-Score?
Revelation Biosciences (REVB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Revelation Biosciences's earnings high quality?
Revelation Biosciences (REVB) reported a net loss of $8.9M while operations used $8.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.